Company news: Eli Lilly and Novartis

Share this article:

Eli Lilly is expanding its Indiana insulin manufacturing operations, marking the first expansion of the company's Indianapolis sites in more than twenty years. The company will provide more details Thursday, but noted in a statement that the new capacity is to meet US demand. The site will make insulin cartridges.

Novartis continues to focus on making Singapore its biotech and manufacturing hub. The company announced Wednesday that it was investing more than $500 million in building a manufacturing facility that will focus on drugs based on cell culture technology. The company said in a statement it expects work to wrap by 2016, and the site will be able to scale up or down to handle a variety of production volumes.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.